6.7 Hypopigmentation, Skin Growths & Skin Cancers
Key Takeaways
- Vitiligo is an acquired autoimmune loss of melanocytes producing sharply defined depigmented patches; albinism is a congenital absence of melanin production.
- Basal cell carcinoma is the most common skin cancer at approximately 80% of diagnosed cases and typically appears as a pearly, rolled-border papule.
- Squamous cell carcinoma accounts for roughly 15% to 20% of cases and often presents as a scaly, crusted or ulcerated nodule.
- Melanoma accounts for only about 1% to 2% of skin cancers but causes the vast majority of skin cancer deaths.
- The ABCDE melanoma criteria are Asymmetry, Border irregularity, Color variation, Diameter greater than 6 millimeters, and Evolving; estheticians must refer, never diagnose.
Last updated: August 2026
6.7 Hypopigmentation, Skin Growths & Skin Cancers
1. Hypopigmentation Disorders
Hypopigmentation results from an abnormal reduction or complete absence of melanin pigment in the skin, hair, or eyes.
┌──────────────────────────────────────────────────────────┐
│ DISORDERS OF HYPOPIGMENTATION │
└────────────────────────────┬─────────────────────────────┘
│
┌──────────────────────────────┼──────────────────────────────┐
▼ ▼ ▼
┌──────────────────────────────┐ ┌──────────────────────────────┐ ┌──────────────────────────────┐
│ VITILIGO │ │ ALBINISM │ │ LEUKODERMA │
├──────────────────────────────┤ ├──────────────────────────────┤ ├──────────────────────────────┤
│ • Autoimmune destruction of │ │ • Congenital / hereditary │ │ • Acquired loss of pigment │
│ epidermal melanocytes │ │ • Absence of TYROSINASE │ │ • Post-trauma, severe burns, │
│ • Stark, chalk-white patches │ │ • Complete melanin absence │ │ chemical exposure, scars │
│ • Symmetrical distribution │ │ • White hair, pale skin, │ │ • Localized hypopigmented │
│ • Extreme photosensitivity │ │ pink/light blue eyes │ │ patches on treated zones │
└──────────────────────────────┘ └──────────────────────────────┘ └──────────────────────────────┘
| Hypopigmentation Disorder | Pathophysiology & Etiology | Clinical Presentation | Esthetic Safety & Management |
|---|---|---|---|
| Vitiligo | Chronic autoimmune disorder where cytotoxic T-lymphocytes target and destroy active epidermal melanocytes | Stark, chalk-white, sharply demarcated macules and patches with hyperpigmented borders; often symmetrical on hands, face, and periorificial areas | Extreme photosensitivity in affected patches; strict broad-spectrum SPF 50+ protection; avoid friction or trauma that induces new patches (Koebner phenomenon) |
| Albinism | Rare congenital, hereditary autosomal recessive disorder characterized by a mutation preventing tyrosinase enzyme synthesis | Complete or near-total absence of melanin pigment in the skin, hair, and irises; pink/light blue eyes with photophobia and nystagmus | Extreme susceptibility to acute UV solar erythema, actinic keratoses, and early skin cancer; cannot tolerate sun exposure; requires continuous physical barrier protection |
| Leukoderma | Acquired, localized loss of skin pigmentation resulting from physical trauma, chemical exposure, burns, or post-surgical scar tissue | Hypopigmented or depigmented patches localized strictly to the site of prior injury or chemical contact | Protective soothing treatments; gentle non-irritating barrier creams; sun protection to prevent surrounding skin from darkening |
2. Benign Skin Growths
Before the malignancies, the esthetician must be able to recognize the far more common benign growths the blueprint lists separately. None may be removed under an Oklahoma esthetics license — OAC 175:10-7-29(a)(1)(G) names the removal of skin tags, moles and angiomas as puncturing the skin — but all must be identified, worked around, and monitored for change.
| Growth | Description | Esthetic handling |
|---|---|---|
| Skin tag (acrochordon) | Small, soft, pedunculated (stalked) flesh-colored outgrowth, most common on the neck, axillae and eyelids where skin rubs | Never remove or ligate. Work around it; avoid catching it in wax or a strip |
| Nevus (mole) | A pigmented or non-pigmented benign malformation of melanocytes; may be flat or raised, congenital or acquired | Never remove. Document location and appearance, and monitor against the ABCDE criteria at each visit |
| Keratoma (callus) | An acquired, superficial, thickened patch of hyperkeratinized epidermis caused by repeated pressure or friction | Softening and gentle surface smoothing only. Cutting implements — razors, Credo blades, graters and rasps — are prohibited under OAC 175:10-7-30(e) |
| Seborrheic keratosis | Waxy, sharply demarcated, "stuck-on" tan-to-brown papule or plaque, increasingly common with age | Benign, but it is frequently mistaken for melanoma. Refer any lesion you cannot confidently place |
| Actinic keratosis | Rough, scaly, sandpaper-textured erythematous patch on chronically sun-exposed skin | Pre-cancerous — a recognized precursor to squamous cell carcinoma. Always refer |
| Verruca (wart) | Rough, raised, keratotic growth caused by human papillomavirus | Contagious. Decline service over the area and refer; see Section 6.3 |
| Angioma | A benign vascular growth; a cherry angioma is a small, bright-red, dome-shaped papule | Never remove. Note that heat and vigorous massage may transiently intensify its appearance |
The one that is not benign
Actinic keratosis is the exception in this table. It is a pre-malignant lesion, and roughly a small percentage progress to squamous cell carcinoma if untreated. A client with widespread actinic damage — the sandpaper texture across the forehead, temples, ears and dorsal hands of someone with a lifetime of sun exposure — should be referred for dermatological evaluation rather than scheduled for a resurfacing series.
The recurring rule
Estheticians describe and refer; they do not diagnose or remove. A growth that has changed in size, shape, color or symptom since the last visit is referred regardless of how benign it appears, because change is the single most reliable warning sign in dermatology.
3. Cutaneous Malignancies (Skin Cancers)
Skin cancer is the most common form of cancer diagnosed in the United States, with over 5 million cases treated annually. Estheticians stand on the front lines of early visual detection, frequently identifying suspicious lesions on the head, neck, face, and décolleté before clients notice them.
┌──────────────────────────────────────────────────────────┐
│ MALIGNANT CUTANEOUS NEOPLASMS (CANCERS) │
└────────────────────────────┬─────────────────────────────┘
│
┌──────────────────────────────┼──────────────────────────────┐
▼ ▼ ▼
┌──────────────────────────────┐ ┌──────────────────────────────┐ ┌──────────────────────────────┐
│ BASAL CELL CARCINOMA (BCC) │ │ SQUAMOUS CELL CARCINOMA(SCC) │ │ MALIGNANT MELANOMA (MM) │
├──────────────────────────────┤ ├──────────────────────────────┤ ├──────────────────────────────┤
│ • ~80% of all skin cancers │ │ • ~15-20% of skin cancers │ │ • ~1-2% of cases (most fatal)│
│ • Arises from Stratum Basale │ │ • Arises from Strat. Spinosum│ │ • Arises from Melanocytes │
│ • Pearly/translucent papule │ │ • Firm, red, scaly nodule or │ │ • Asymmetrical, multi-colored│
│ • Rolled borders, telangiect.│ │ crusted non-healing ulcer │ │ rapidly changing lesion │
│ • Slow growth; rarely metast.│ │ • Potential lymph metastasis │ │ • Rapid lymph/blood metast. │
└──────────────────────────────┘ └──────────────────────────────┘ └──────────────────────────────┘
Basal Cell Carcinoma (BCC)
- Epidemiology: The most frequent skin cancer, accounting for approximately 80% of all diagnosed cases.
- Origin: Arises from abnormal, non-keratinizing epithelial cells within the stratum basale of the epidermis.
- Clinical Presentation: Classically appears as a smooth, pearly or translucent pink papule or nodule with visible, branching surface telangiectasias (spider vessels) and distinctive elevated rolled borders, often developing a central depression or non-healing ulcer that bleeds easily.
- Prognosis: Slow-growing and rarely metastasizes to distant organs, but causes extensive localized destruction of underlying skin, cartilage, and bone if left untreated.
Squamous Cell Carcinoma (SCC)
- Epidemiology: The second most common form of skin cancer, comprising approximately 15% to 20% of cases.
- Origin: Arises from atypical keratinocytes in the stratum spinosum of the epidermis. Often preceded by actinic keratosis (a rough, scaly precancerous lesion caused by UV exposure).
- Clinical Presentation: Appears as a firm, persistent, red or flesh-colored nodule, or a rough, scaly, crusted plaque with elevated edges that may ulcerate and bleed persistently without healing.
- Prognosis: Grows more rapidly than BCC and possesses significant potential to metastasize to regional lymph nodes and internal organs if neglected.
Malignant Melanoma
- Epidemiology: Accounts for approximately 1% to 2% of skin cancer cases, but is responsible for the vast majority of skin cancer-related fatalities.
- Origin: Originates from the malignant transformation of melanocytes in the stratum basale or within pre-existing pigmented nevi (moles).
- Clinical Presentation: An asymmetrical, irregular, multi-colored macule, plaque, or nodule that changes dynamically in size, shape, and topography.
- Prognosis: Highly aggressive; rapidly invades the papillary and reticular dermis, gaining direct access to lymphatic channels and blood vessels to metastasize systemically to the lungs, liver, brain, and bones.
4. The ABCDE Melanoma Screening Criteria
The American Academy of Dermatology developed the standardized ABCDE framework to assist healthcare providers and skin care professionals in identifying early morphologic changes indicative of malignant melanoma.
┌──────────────────────────────────────────────────────────┐
│ ABCDE MELANOMA SCREENING FRAMEWORK │
└────────────────────────────┬─────────────────────────────┘
│
┌───────────────┬───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
│ CRITERION │ BENIGN CHARACTERISTIC │ SUSPICIOUS MALIGNANT SIGN │ CLINICAL MEANING │
├───────────────┼───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
│ A: Asymmetry │ Symmetrical; halves match │ Asymmetrical; halves mismatch │ Unequal cellular growth │
│ B: Border │ Smooth, even, distinct edges │ Irregular, scalloped, notched │ Invasive radial spread │
│ C: Color │ Single uniform brown/tan shade│ Variegated (black, blue, red) │ Multi-clone pigment surge │
│ D: Diameter │ Small (<6 mm / pencil eraser) │ Large (>6 mm / 1/4 inch) │ Advanced volumetric expansion │
│ E: Evolving │ Stable; unchanged over years │ Changing size, shape, bleeding│ Dynamic malignant evolution │
└───────────────┴───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘
- A = Asymmetry: When an imaginary line is drawn through the center of the lesion, the two halves do not match in shape, size, or contour.
- B = Border Irregularity: The outer perimeter of the lesion is uneven, scalloped, notched, blurred, ragged, or poorly defined.
- C = Color Variation: The lesion does not display a single uniform shade, but contains multiple variegated hues (shades of tan, dark brown, jet black, interspersed with red, white, or slate-blue zones).
- D = Diameter: The lesion measures greater than 6 millimeters (mm) across (roughly the size of a standard pencil eraser), although early melanomas can be smaller.
- E = Evolving: The lesion is dynamically changing over time in size, shape, surface elevation, color, or develops new onset symptoms such as itching, tenderness, oozing, or spontaneous bleeding. Evolution is the most critical warning sign of malignancy.
5. Professional Scope & Referral Protocol
When an esthetician discovers an undiagnosed, atypical, or suspicious lesion on a client, adhering to professional and ethical referral protocols is legally and clinically mandatory.
┌──────────────────────────────────────────────────────────┐
│ PROFESSIONAL SUSPICIOUS LESION PROTOCOL │
└────────────────────────────┬─────────────────────────────┘
│
┌──────────────────────────────────────────────┴──────────────────────────────────────────────┐
▼ ▼
┌──────────────────────────────┐ ┌──────────────────────────────┐
│ 1. IMMEDIATE SERVICE ACTION │ │ 2. NON-DIAGNOSTIC COMMUNICATION│
├──────────────────────────────┤ ├──────────────────────────────┤
│ • DO NOT perform extractions │ │ • Maintain calm, neutral tone│
│ • DO NOT apply chemical peel │ │ • NEVER state cancer or BCC │
│ • DO NOT wax or abrade area │ │ • State: "I notice an unusual│
│ • Work safely around lesion │ │ spot that should be checked│
│ or suspend service │ │ by a medical physician." │
└──────────────┬───────────────┘ └──────────────┬───────────────┘
│ │
└──────────────────────────────────────┬─────────────────────────────────────────────────────┘
│
┌──────────────────────┴──────────────────────┐
▼ ▼
┌──────────────────────────────┐ ┌──────────────────────────────┐
│ 3. OBJECTIVE DOCUMENTATION │ │ 4. PHYSICIAN REFERRAL │
├──────────────────────────────┤ ├──────────────────────────────┤
│ • Record location on chart │ │ • Recommend prompt evaluation│
│ • Note morphological traits │ │ by board-certified derm. │
│ • Note date client notified │ │ • Require medical clearance │
│ • Keep strictly factual │ │ prior to advanced services │
└──────────────────────────────┘ └──────────────────────────────┘
Exam Trap Alert — Scope & Pigmentation Traps:
- Melasma Trigger Trap: Melasma is triggered by hormones + UV radiation + infrared HEAT. Giving a hot steam facial to a melasma client worsens hyperpigmentation!
- BCC Appearance: Classic description is "pearly, translucent papule with rolled borders and telangiectasias".
- Melanoma Deadliness: Melanoma accounts for only 1–2% of skin cancers but causes the vast majority of skin cancer deaths.
- Esthetic Scope Law: Estheticians NEVER diagnose. Always refer to a board-certified dermatologist.
Test Your Knowledge
Under the dermatological ABCDE criteria for melanoma screening, what does the letter 'E' specifically represent, and why is it considered the most critical clinical indicator?
A
B
C
D
Test Your Knowledge
A 32-year-old female client who is pregnant presents with symmetrical, bilateral hyperpigmented brown macules and patches across her forehead, upper lip, and cheekbones. Which condition is this, and what is its primary physiological etiology?
A
B
C
D